We believe in the power of strong partnerships and collaborations to unlock new opportunities for novel therapeutics that will benefit patients worldwide.

Partnerships

We are seeking partnerships to:

  • Advance our early-stage assets into clinical development and commercialization. Our current focus is in cardiovascular disease, oncology and neurodegeneration. We have three assets in stroke and heart attack that we are seeking to partner to advance into clinical studies for territories outside of China.
  • Leverage our platform technologies in protein-protein interference blockade and protein degradation to develop novel peptides against targets identified by partners. Our platforms are versatile and we can rapidly generate lead compounds for diverse diseases.

Current Partnerships

Yaboa Pharmaceutical logo

Yabao – K13

Our current partnership with Yabao Pharmaceutical is to advance the development and commercialization of K13, an interference peptide that we developed for the treatment of stroke. It has the potential to be the first- in-class PTEN- targeting neuroprotective agent for stroke patients. Yabao has rights for China only. We retain freedom to operate in the rest of the world.

Simcere Pharmaceutical logo

Simcere – PP-001

Our partnership with Simcere Pharmaceutical is for the development and commercialization of PP-001 targeting DAPK1 as a potential treatment for stroke. PP-001 is a peptide that we developed using our Chaperone-mediated Autophagy Protein Degradation Technology (CHAPTAC). Simcere has rights for China only. We retain freedom to operate in the rest of the world.

Primedicine logo

Primedicine – PP-002

Our partnership with Primedicine is for the development and commercialization of PP-002, an interference peptide that we developed targeting zD17/JNK as a potential treatment for heart attack. Primedicine has rights for China only. We retain freedom to operate in the rest of the world.